Applied BioCode Corporation

6598

KYG0488D1051

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 18:00:00 2024-05-12 EDT			5-day change	1st Jan Change
19.9 ^TWD	-0.75%		-0.50%	-21.34%

04-15	Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only	CI
03-21	Applied BioCode Announces CEO Changes	CI

Applied BioCode Corporation Announces the Resignation of Michael Sean Aye as Research and Development Officer

September 22, 2023 at 11:14 pm

Applied BioCode Corporation announced the resignation of Michael Sean Aye as research and development officer, effective September 23, 2023. Reason for the change: Personal career planning.

Latest news about Applied BioCode Corporation

Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only	04-15	CI
Applied BioCode Announces CEO Changes	03-21	CI
Applied BioCode Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Applied BioCode Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Applied BioCode Appoints Beth Laderman as Chief Scientific Officer	23-09-28	CI
Applied BioCode Corporation Announces the Resignation of Michael Sean Aye as Research and Development Officer	23-09-22	CI
Applied BioCode Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-27	CI
Applied BioCode Corporation Announces the Change of Representative of Institutional Director	23-06-14	CI
Applied Biocode Corporation Announces the Launch of the Fungal Panel Assay for Research Use	23-06-12	CI
Applied BioCode Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Applied BioCode Corporation Announces Distribution Agreement with Medline Industries	23-05-08	CI
Applied BioCode Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
Applied BioCode Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
Applied BioCode Corporation Appoints Liang-Kai Huang as Corporate Governance Officer	23-03-13	CI
Applied Biocode Corporation Announces Revenue Results for the Fourth Quarter and Full Year of 2022	23-02-27	CI
Applied BioCode Corporation Announces Resignation of Craig Griz Adams as Sales Director	23-01-04	CI
Applied BioCode Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Applied BioCode Corporation(TWSE:6598) dropped from S&P Global BMI Index	22-09-19	CI
Applied BioCode Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-29	CI
Applied Biocode Corporation Announces the Change of Sales Director	22-08-25	CI
Applied BioCode Corporation Announces the Change of Vice President of Operation	22-08-25	CI
Applied BioCode Corporation Announces Change of Sales Director	22-05-17	CI
Applied BioCode Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Applied BioCode Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-27	CI
Applied BioCode Appoints Chris Bernard as Chief Executive Officer	22-03-24	CI

Chart Applied BioCode Corporation

Duration

Period

More charts

Applied BioCode Corp is a is a Taiwan-based company mainly engaged in the provision of automated multiple detection platforms, various application development of detection platforms, as well as the research, development and sale of infectious disease diagnostic reagents. The Company's main products include digital barcode magnetic beads (BMB), optical analyzers, in vitro diagnostic reagents and others. The Company sells in the United States, Europe and Asia markets.

Sector

Biotechnology & Medical Research

Calendar

2024-05-26 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

19.9 TWD

Average target price

22 TWD

Spread / Average Target

+10.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
APPLIED BIOCODE CORPORATION	-21.34%	50.18M
EXACT SCIENCES CORPORATION	-24.86%	10.26B
IOVANCE BIOTHERAPEUTICS, INC.	+33.83%	3.04B
GUARDANT HEALTH, INC.	-11.28%	2.94B
BGI GENOMICS CO., LTD.	-12.92%	2.19B
VERACYTE, INC.	-18.21%	1.72B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+60.76%	1.4B
CAREDX, INC	+24.83%	780M
SEEGENE, INC.	-4.59%	736M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-22.45%	560M

Bio Diagnostics & Testing